NCT02194738 2026-03-18
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
Clinical Trials
7 trialsNCT00883480 2022-06-13
SLAT
Spanish Lung Cancer Group
Phase NA Completed
NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
NCT00125372 2019-01-08
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT00085280 2014-03-31
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase NA Completed
NCT01776684 2013-01-28
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Samsung Medical Center
Phase NA Unknown
NCT00903292 2009-05-18
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
National Cheng-Kung University Hospital
Phase NA Unknown